Tarveda Therapeutics
Watertown
About Tarveda Therapeutics
Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors. The company's HSP90 targeted drug conjugate platform with lead drug candidate PEN-866 selectively binds in tumors to the activated form of Heat Shock Protein 90 (HSP90) and releases its potent topoisomerase 1 inhibitor payload, SN38 and it also develops a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine, small cell lung and other solid tumors, enabling companies to extend the lives of patients with hard to treat cancers while minimizing potential toxicities.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $148.4M
- Last round: Series Unknown (Sep 2021)
- Website: tarvedatx.com
- Phone: (617)923-4100
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/tarveda-therapeutics-40426 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.